APA (7th ed.) Citation

C, Z., SS, Z., XR, L., BM, W., NM, L., LY, F., . . . JP, P. (2024). [Corrigendum] Enhanced antitumor activity by the combination of dasatinib and combretastatin A‑4 in vitro and in vivo. Oncology reports, 52(4), . https://doi.org/10.3892/or.2024.8783

Chicago Style (17th ed.) Citation

C, Zhang, et al. "[Corrigendum] Enhanced Antitumor Activity by the Combination of Dasatinib and Combretastatin A‑4 in Vitro and in Vivo." Oncology Reports 52, no. 4 (2024). https://doi.org/10.3892/or.2024.8783.

MLA (9th ed.) Citation

C, Zhang, et al. "[Corrigendum] Enhanced Antitumor Activity by the Combination of Dasatinib and Combretastatin A‑4 in Vitro and in Vivo." Oncology Reports, vol. 52, no. 4, 2024, https://doi.org/10.3892/or.2024.8783.